两种疗法主要有两点不同:① ADP-A2M4CD8在Afami-cel的基础上加了CD8α同源二聚体;② 指征不同,Afami-cel指征MAGE-A4阳性的肉瘤,ADP-A2M4CD8则对准MAGE-4阳性率较高的其他实体瘤如非小细胞肺癌、卵巢癌、头颈癌、胃食管癌和膀胱癌。
数据显示,接受单次T细胞疗法治疗后,晚期卵巢癌、尿路上皮癌和头颈癌患者的客观缓解率(ORR)提升至52%,中位缓解期延长至约20周。 本次所发布的数据显示,经过单剂ADP-A2M4CD8治疗后,晚期卵巢癌、尿路上皮癌和头颈癌患者中的ORR已上升至52%(ESMO大会上报告的ORR为44%),这些患者先前接受过抗癌治疗。此外,对于整个...
数据显示,接受单次T细胞疗法治疗后,晚期卵巢癌、尿路上皮癌和头颈癌患者的客观缓解率(ORR)提升至52%,中位缓解期延长至约20周。 本次所发布的数据显示,经过单剂ADP-A2M4CD8治疗后,晚期卵巢癌、尿路上皮癌和头颈癌患者中的ORR已上升至52%(ESMO大会上报告的ORR为44%),这些患者先前接受过抗癌治疗。此外,对于整个...
This is a global Phase 2 clinical trial designed to evaluate ADP-A2M4CD8 TCR T-cell therapy alone or in combination with nivolumab in patients with recurrent or metastatic platinum resistant ovarian cancer (P...
TPS708#Background:ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy consists of autologous CD4+ and CD8+ T-cells genetically modified to target melanoma-associated antigen A4 (MAGE-A4) in patients (pts) with advanced cancers who are human leukocyte antigen A*02 eligible. In the late-line ...
2022年11月11日,细胞治疗公司Adaptimmune Therapeutics发布了旗下靶向MAGE-A4的T细胞疗法的最新临床1期数据,接受单次T细胞疗法治疗后,晚期卵巢癌、尿路上皮癌和头颈癌患者的客观缓解率(ORR)提升至52%,中位缓解期延长至约20周。本次所发布的数据显示,经过单剂ADP-A2M4CD8治疗后,晚期卵巢癌、尿路上皮癌和头颈癌患者...
ADP-A2M4CD8是新一代T细胞疗法,旨在靶向 MAGE-A4 阳性肿瘤,并表达 CD8α 共受体。CD8α的共表达增加CD8+杀伤细胞对CD4+辅助T细胞的能力,同时维持或增强CD4+辅助T细胞功能(即产生炎症因子IFN-γ和IL-2)。 初步的体外肿瘤细胞杀伤试验证实,与第一代产品相比,ADP-A2M4D8更有效,更好地参与免疫系统。
The ongoing Phase 1 SURPASS trial (NCT04044859) of ADP-A2M4CD8 in HLA-A*02-eligible participants demonstrated an acceptable benefit to risk profile with responses across multiple MAGE-A4+ solid tumours, including platinum-resistant ovarian cancer, with an overall response rate on 09 March 2023 ...
349 Background: ADP-A2M4CD8 is a specific peptide enhanced affinity receptor mixed CD4+ and CD8+ T-cell therapy targeting the cancer testis antigen MAGE-A4 and modified with addition of a CD8α co-receptor designed to provide additional functionality to CD4+ T-cells. ADP-A2M4CD8 has ...
Introduction ADP-A2M4CD8, a next-generation specific peptide enhanced affinity receptor (SPEAR) T-cell therapy supplemented with a CD8α co-receptor, is being evaluated in the Phase 1 SURPASS trial (NCT04044859) in multiple solid tumours, including ovarian cancer. Promising anti-tumour activity, ...